NFKB1 and rheumatoid arthritis: Several studies have demonstrated the effect of NFκB inhibition in the activation of RA-SFs ex vivo19–23, and preclinical therapeutic schemes including small molecule targeting of IKK2 or virus-based vectors expressing inhibitors of NFκB activation have been tested in RA models; therapeutic effects have been shown to mainly affect immune cell activation24–28.